Zhitong Finance App News, Li's Pharmaceutical Factory (00950.HK) announced that on September 25, 2024, China's National Drug Administration accepted clinical trial applications for recombinant amfibopeptide injections, with acceptance numbers CXSL2400638 and CXSL2400639. This is the first clinical trial registration application for this product, and the submitted clinical plans include phase I (single dose and multiple doses) and phase II clinical plans.

Zhitongcaijing · 10/14 13:57
Zhitong Finance App News, Li's Pharmaceutical Factory (00950.HK) announced that on September 25, 2024, China's National Drug Administration accepted clinical trial applications for recombinant amfibopeptide injections, with acceptance numbers CXSL2400638 and CXSL2400639. This is the first clinical trial registration application for this product, and the submitted clinical plans include phase I (single dose and multiple doses) and phase II clinical plans.